Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
30.36
-0.76 (-2.43%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.33 - 30.89
52 week 19.91 - 31.20
Open 30.81
Vol / Avg. 2.31M/1.85M
Mkt cap 8.50B
P/E 166.91
Div/yield     -
EPS 0.18
Shares 279.79M
Beta 1.35
Inst. own 97%
Apr 28, 2015
Q2 2015 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 3, 2015
Hologic Inc Annual Shareholders Meeting - 8:30AM EST - Add to calendar
Jan 28, 2015
Q1 2015 Hologic Inc Earnings Call - Webcast
Jan 28, 2015
Q1 2015 Hologic Inc Earnings Release
Jan 13, 2015
Hologic Inc at JPMorgan Healthcare Conference
Nov 5, 2014
Q4 2014 Hologic Inc Earnings Call - Webcast
Nov 5, 2014
Q4 2014 Hologic Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 4.47% 0.68%
Operating margin 14.83% 10.76%
EBITD margin - 34.15%
Return on average assets 1.42% 0.20%
Return on average equity 5.62% 0.86%
Employees 5,351 -
CDP Score - -

Address

35 Crosby Dr
BEDFORD, MA 01730-1450
United States - Map
+1-781-9997300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women. The Company's core business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company sells and service its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company offers a wide range of diagnostic products which are used primarily to aid in the diagnosis of human diseases and screen donated human blood. The Company's molecular diagnostics products include the Company's Aptima family of assays based on its Transcription-Mediated-Amplification, or TMA, technology, its Cervista products based on its Invader chemistry and its advanced instrumentation (Panther, Tigris and HTA).

Officers and directors

David R. LaVance Jr. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Stephen P. MacMillan President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claus Egstrand Senior Vice President, General Manager - International
Bio & Compensation  - Reuters
Roger D. Mills Group Senior Vice President, General Manager - Service and Operations
Age: 58
Bio & Compensation  - Reuters
David P. Harding Senior Vice President - Corporate Strategy
Age: 48
Bio & Compensation  - Reuters
John Griffin General Counsel
Bio & Compensation  - Reuters
Jonathan N. Christodoro Independent Director
Age: 38
Bio & Compensation  - Reuters